

AMENDMENT

Please amend the application without prejudice, without admission, without surrender of subject matter and without intention of creating any estoppel as to equivalents, as follows.

In the Claims

1. (Original) A conjugate comprising a first sequence and a second sequence, wherein the first sequence comprises a nuclear membrane translocation transport protein or a polynucleotide encoding a nuclear membrane translocation transport protein and the second sequence comprises Notch intracellular domain (Notch IC) ~~a polypeptide or a polynucleotide that modulates Notch signaling~~ encoding Notch IC.

2. (Original) The conjugate according to claim 1, wherein the conjugate is a fusion protein.

3-14. (Cancelled)

15. (Original) The conjugate according to claim 14, wherein the second sequence further comprises a RAM domain, a PEST sequence, an OPA sequence or a polynucleotide encoding a RAM domain, a PEST sequence or an OPA sequence.

16-21. (Cancelled)

22. (Original) The conjugate according to claim 1, wherein the first sequence is a herpesvirus VP22 protein (VP22) or a fragment thereof that retains a VP22 transport function.

23. (Original) The conjugate according to claim 22, wherein the first sequence is a full length VP22 sequence.

24. (Original) The conjugate according to claim 22, wherein the fragment of VP22 comprises:

from about amino acid 60 to about amino acid 301 of the full length VP22 sequence, or
from about amino acid 159 to about amino acid 301 of the full length VP22 sequence.

25. (Cancelled)

26. (Cancelled)

27. (Original) The conjugate according to claim 1, wherein the first sequence is an HIV tat protein, or a variant thereof that retains a transport function.

28. (Original) A polynucleotide sequence encoding the conjugate of claim 1.

29. (Original) An expression vector comprising the polynucleotide sequence of claim 28.

30. (Original) A host cell transformed with the expression vector of claim 29.
31. (Original) A method for preparing a conjugate comprising culturing the host cell of claim 30 under conditions which provide for the expression of the conjugate.
32. (Original) A conjugate prepared by the method of claim 31.
33. (Original) A method of transforming a cell with a protein for Notch signalling modulation or a polynucleotide sequence which encodes therefor, the method comprising introducing the expression vector of claim 29 into the cell.
34. (Original) A composition comprising the conjugate of claim 1 and a pharmaceutically acceptable excipient, diluent or carrier.
35. (Original) A method for the prevention or treatment of disease or infection comprising administering the composition of claim 34 to a subject in need thereof.
36. (Original) The method according to claim 35, wherein the disease is a T-cell mediated disease.